All these findings suggested that PMEPA1-b inhibited prostate tumor growth in AR signaling dependent and independent way, well-matched with the findings that reduced or loss of expression of PMEPA1-b strongly indicated adverse clinical outcomes. Here, PMEPA1 is linked to prostate neoplasm.